DK2826770T3 - Acylguanidin-forbindelser med antiviral aktivitet - Google Patents
Acylguanidin-forbindelser med antiviral aktivitet Download PDFInfo
- Publication number
- DK2826770T3 DK2826770T3 DK13197255.6T DK13197255T DK2826770T3 DK 2826770 T3 DK2826770 T3 DK 2826770T3 DK 13197255 T DK13197255 T DK 13197255T DK 2826770 T3 DK2826770 T3 DK 2826770T3
- Authority
- DK
- Denmark
- Prior art keywords
- compound
- virus
- pharmaceutical composition
- compounds
- mixture
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C279/00—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups
- C07C279/20—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups containing any of the groups, X being a hetero atom, Y being any atom, e.g. acylguanidines
- C07C279/22—Y being a hydrogen or a carbon atom, e.g. benzoylguanidines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
- A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/62—Oxygen or sulfur atoms
- C07D213/69—Two or more oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/06—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
- C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D307/38—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D307/54—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
- C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
- C07D333/06—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
- C07D333/22—Radicals substituted by doubly bound hetero atoms, or by two hetero atoms other than halogen singly bound to the same carbon atom
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Virology (AREA)
- Oncology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Communicable Diseases (AREA)
- Molecular Biology (AREA)
- AIDS & HIV (AREA)
- Tropical Medicine & Parasitology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)
- Heterocyclic Compounds Containing Sulfur Atoms (AREA)
- Furan Compounds (AREA)
- Pyridine Compounds (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
Claims (13)
1. Forbindelse, hvori forbindelsen er valgt fra gruppen bestående af: (3 -benzoyl)cinnamoylguanidin, 3 (indan-4-yl)-propenoylguanidin, 2,3-methylendioxycinnamoylguanidin, og farmaceutisk acceptable salte deraf.
2. Forbindelse ifølge krav 1, hvori amino- eller iminogrupperne i guanidyldelen af forbindelserne med formlen I findes som fri base, som hydrat, som organisk eller uorganisk salt eller kombinationer deraf.
3. Forbindelse ifølge krav 1 eller 2, hvori forbindelsen foreligger i form af et salt eller et additionsprodukt eller foreligger på vandfri eller solvatiseret form.
4. Farmaceutisk sammensætning omfattende en forbindelse ifølge et hvilket som helst af kravene 1 til 3, eventuelt i kombination med ét eller flere farmaceutisk acceptable bærestoffer eller hjælpestoffer.
5. Farmaceutisk sammensætning ifølge krav 4, som endvidere omfatter ét eller flere kendte antivirale midler.
6. Forbindelse ifølge et hvilket som helst af kravene 1 til 3 eller farmaceutisk sammensætning ifølge krav 4 eller krav 5 til anvendelse ved nedbringelse, forhaling eller på anden måde hæmning af vækst og/eller replikation af et virus.
7. Forbindelse ifølge et hvilket som helst af kravene 1 til 3 eller farmaceutisk sammensætning ifølge krav 4 eller krav 5 til anvendelse ved forebyggelse af infektion af en for et virus udsat celle.
8. Forbindelse ifølge et hvilket som helst af kravene 1 til 3 eller farmaceutisk sammensætning ifølge krav 4 eller krav 5 til anvendelse ved terapeutisk eller profylaktisk behandling af et individ, der er udsat for eller inficeret med et virus.
9. Forbindelse ifølge et hvilket som helst af kravene 1 til 3 eller farmaceutisk sammensætning ifølge krav 4 eller krav 5, hvor forbindelsen eller den farmaceutiske sammensætning findes sammen med ét eller flere kendte antivirale midler, til anvendelse ved terapeutisk eller profylaktisk behandling af et individ, der er udsat for eller inficeret med et virus.
10. Forbindelse eller farmaceutisk sammensætning til anvendelse ifølge et hvilket som helst af kravene 6 til 9, hvor virusset er valgt blandt Lentivirus- og Flavivirus-familierne.
11. Forbindelse eller farmaceutisk sammensætning til anvendelse ifølge krav 10, hvor virusset er valgt fra gruppen bestående af hepatitis-C-virus (HCV), humant immun-defektvirus (HIV) og dengue-virus.
12. Forbindelse eller farmaceutisk sammensætning til anvendelse ifølge krav 11, hvor virusset er valgt fra gruppen bestående af HCV, HIV-1, HIV-2 og dengue-virus.
13. Forbindelse eller farmaceutisk sammensætning til anvendelse ifølge et hvilket som helst af kravene 8 til 12, hvor det individ, der undergår terapeutisk eller profylaktisk behandling, er et pattedyr valgt fra gruppen bestående af menneske, primat, husdyr, kæledyr, forsøgsdyr eller indfanget vildt dyr.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU2005903360A AU2005903360A0 (en) | 2005-06-24 | Anti-viral compounds and methods | |
EP06741271.8A EP1902017B1 (en) | 2005-06-24 | 2006-06-23 | Antiviral acylguanidine compounds |
Publications (1)
Publication Number | Publication Date |
---|---|
DK2826770T3 true DK2826770T3 (da) | 2019-01-07 |
Family
ID=37570036
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK06741271.8T DK1902017T3 (da) | 2005-06-24 | 2006-06-23 | Antivirale acylguanidinforbindelser |
DK13197255.6T DK2826770T3 (da) | 2005-06-24 | 2006-06-23 | Acylguanidin-forbindelser med antiviral aktivitet |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK06741271.8T DK1902017T3 (da) | 2005-06-24 | 2006-06-23 | Antivirale acylguanidinforbindelser |
Country Status (17)
Country | Link |
---|---|
US (3) | US8669280B2 (da) |
EP (2) | EP1902017B1 (da) |
JP (2) | JP5373392B2 (da) |
KR (2) | KR20140072101A (da) |
CN (2) | CN103274970B (da) |
AU (1) | AU2006261593B2 (da) |
BR (2) | BRPI0612309B8 (da) |
CA (1) | CA2612403C (da) |
DK (2) | DK1902017T3 (da) |
ES (2) | ES2491217T3 (da) |
HK (2) | HK1109615A1 (da) |
NZ (3) | NZ596107A (da) |
PL (2) | PL1902017T3 (da) |
PT (2) | PT2826770T (da) |
SG (1) | SG163517A1 (da) |
WO (1) | WO2006135978A1 (da) |
ZA (1) | ZA200800256B (da) |
Families Citing this family (39)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2004112687A2 (en) * | 2003-06-26 | 2004-12-29 | Biotron Limited | Antiviral acylguanidine compounds and methods |
DK1902017T3 (da) * | 2005-06-24 | 2014-06-30 | Biotron Ltd | Antivirale acylguanidinforbindelser |
US8518960B2 (en) | 2007-05-23 | 2013-08-27 | Siga Technologies, Inc. | Antiviral drugs for treatment or prevention of dengue infection |
ES2563477T3 (es) * | 2007-08-03 | 2016-03-15 | Biotron Limited | Composiciones antivirales para tratar la hepatitis C a base de 5-(1-metilpirazol-4-il)2-naftoilguanidina y 2'-C-metiladenosina o 2'-C-metilcitidina |
AU2013219202B2 (en) * | 2007-08-03 | 2016-12-08 | Biotron Limited | Hepatitis C antiviral compositions and methods |
EP2177505A4 (en) * | 2007-08-10 | 2011-08-31 | Astellas Pharma Inc | BICYCLIC ACYLGUANIDINE DERIVATIVE |
WO2010090305A1 (ja) * | 2009-02-09 | 2010-08-12 | アステラス製薬株式会社 | 置換アシルグアニジン誘導体 |
WO2010090304A1 (ja) * | 2009-02-09 | 2010-08-12 | アステラス製薬株式会社 | アシルグアニジン誘導体 |
TW201116281A (en) | 2009-08-06 | 2011-05-16 | Astellas Pharma Inc | N atom containing ring acylguanidine derivatives |
CR20170278A (es) | 2010-07-22 | 2017-09-29 | Gilead Sciences Inc | Métodos y compuestos para tratar infecciones virales por paramyxoviridae |
US9126106B1 (en) | 2010-11-05 | 2015-09-08 | Wms Gaming, Inc. | Promotional content coordination in wagering game machines |
MX2013006951A (es) * | 2010-12-16 | 2013-10-03 | Abbvie Inc | Compuestos antivirales. |
TWI740546B (zh) | 2014-10-29 | 2021-09-21 | 美商基利科學股份有限公司 | 製備核糖苷的方法 |
SG10202001878WA (en) | 2015-09-16 | 2020-04-29 | Gilead Sciences Inc | Methods for treating arenaviridae and coronaviridae virus infections |
KR102607599B1 (ko) * | 2017-02-08 | 2023-11-28 | 바이오트론 리미티드 | 인플루엔자의 치료 방법 |
KR102460968B1 (ko) | 2017-03-14 | 2022-11-01 | 길리애드 사이언시즈, 인코포레이티드 | 고양이 코로나바이러스 감염의 치료 방법 |
WO2018204198A1 (en) | 2017-05-01 | 2018-11-08 | Gilead Sciences, Inc. | Crystalline forms of (s) 2 ethylbutyl 2 (((s) (((2r,3s,4r,5r) 5 (4 aminopyrrolo[2,1-f] [1,2,4]triazin-7-yl)-5-cyano-3,4-dihydroxytetrahydrofuran-2 yl)methoxy)(phenoxy) phosphoryl)amino)propanoate |
CA3077489A1 (en) | 2017-07-11 | 2019-01-17 | Gilead Sciences, Inc. | Compositions comprising an rna polymerase inhibitor and cyclodextrin for treating viral infections |
BR112022010161A2 (pt) * | 2019-11-26 | 2022-08-09 | Biotron Ltd | Método para tratar a infecção por hiv-1 e regular a função do sistema imunológico, e, uso de um ou mais agentes antirretrovirais e n-carbamimidoil-5-(1-metilpirazol-4-il)naftaleno-2-carboxamida |
CA3163424A1 (en) | 2020-01-27 | 2021-08-05 | Gilead Sciences, Inc. | Methods for treating sars cov-2 infections |
JP2023516087A (ja) | 2020-03-12 | 2023-04-17 | ギリアード サイエンシーズ, インコーポレイテッド | 1’-シアノヌクレオシドを調製する方法 |
KR20220164784A (ko) | 2020-04-06 | 2022-12-13 | 길리애드 사이언시즈, 인코포레이티드 | 1'-시아노 치환된 카르바뉴클레오시드 유사체의 흡입 제형 |
TW202203941A (zh) | 2020-05-29 | 2022-02-01 | 美商基利科學股份有限公司 | 瑞德西韋之治療方法 |
CR20220675A (es) | 2020-06-24 | 2023-02-15 | Gilead Sciences Inc | Análogos de nucleósido de 1´- ciano y usos de los mismos |
EP4200301A1 (en) | 2020-08-24 | 2023-06-28 | Gilead Sciences, Inc. | Phospholipid compounds and uses thereof |
KR20230057411A (ko) | 2020-08-27 | 2023-04-28 | 길리애드 사이언시즈, 인코포레이티드 | 바이러스 감염 치료를 위한 화합물 및 방법 |
TWI811812B (zh) | 2020-10-16 | 2023-08-11 | 美商基利科學股份有限公司 | 磷脂化合物及其用途 |
US20230000873A1 (en) | 2021-05-26 | 2023-01-05 | Gilead Sciences, Inc. | Phospholipid formulations of 1'-cyano substituted carba-nucleoside analogs |
AU2022328698A1 (en) | 2021-08-18 | 2024-02-01 | Gilead Sciences, Inc. | Phospholipid compounds and methods of making and using the same |
WO2023092180A1 (en) * | 2021-11-24 | 2023-06-01 | Biotron Limited | Methods of treating sars-cov-2 infection |
WO2023167938A1 (en) | 2022-03-02 | 2023-09-07 | Gilead Sciences, Inc. | Compounds and methods for treatment of viral infections |
TW202400185A (zh) | 2022-03-02 | 2024-01-01 | 美商基利科學股份有限公司 | 用於治療病毒感染的化合物及方法 |
US20230382940A1 (en) | 2022-03-03 | 2023-11-30 | Gilead Sciences, Inc. | Antiviral compounds and methods of making and using the same |
WO2023168194A1 (en) | 2022-03-03 | 2023-09-07 | Gilead Sciences, Inc. | Antiviral compounds and methods of making and using the same |
WO2023167055A1 (ja) * | 2022-03-03 | 2023-09-07 | 日本曹達株式会社 | 抗ウイルス剤 |
US20240009220A1 (en) | 2022-06-06 | 2024-01-11 | Gilead Sciences, Inc. | Methods for treatment of viral infections |
US20240051962A1 (en) | 2022-06-29 | 2024-02-15 | Gilead Sciences, Inc. | Solid forms of a nucleoside analogue and uses thereof |
WO2024006461A1 (en) | 2022-06-30 | 2024-01-04 | Gilead Sciences, Inc. | Solid forms of a nucleoside analogue and uses thereof |
CN115260100B (zh) * | 2022-08-08 | 2023-12-12 | 赛诺瑞生物医药技术(无锡)有限公司 | 一种用于制备冠状病毒治疗药物的取代酰基胍类化合物和用途 |
Family Cites Families (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2734904A (en) | 1956-02-14 | Xcxnhxc-nh | ||
US4251545A (en) | 1979-09-19 | 1981-02-17 | Gaf Corporation | Fungicidal process using 1-(alkoxyaroyl)guanidines |
US4544670A (en) * | 1982-08-24 | 1985-10-01 | William H. Rorer, Inc. | Method of treating coccidiosis with acyl guanidines |
JPH0218632A (ja) | 1988-07-07 | 1990-01-22 | Matsushita Electric Ind Co Ltd | 論理ゲート評価装置と論理ゲート評価方法 |
DE3929582A1 (de) * | 1989-09-06 | 1991-03-07 | Hoechst Ag | Benzoylguanidine, verfahren zu ihrer herstellung, ihre verwendung als medikament sowie sie enthaltendes medikament |
IL109570A0 (en) * | 1993-05-17 | 1994-08-26 | Fujisawa Pharmaceutical Co | Guanidine derivatives, pharmaceutical compositions containing the same and processes for the preparation thereof |
DE4328869A1 (de) | 1993-08-27 | 1995-03-02 | Hoechst Ag | Ortho-substituierte Benzoylguanidine, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament |
DE4421536A1 (de) * | 1994-06-20 | 1995-12-21 | Hoechst Ag | Perfluoralkylgruppen tragende phenylsubstituierte Alkenylcarbonsäure-guanidine, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament |
JPH08225513A (ja) * | 1994-12-21 | 1996-09-03 | Kanebo Ltd | ナフトイルグアニジン誘導体 |
DE19518796A1 (de) * | 1995-05-22 | 1996-11-28 | Hoechst Ag | Fluorphenylsubstituierte Alkenylcarbonsäure-guanidine, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament |
DE19527305A1 (de) | 1995-07-26 | 1997-01-30 | Hoechst Ag | Substituierte Zimtsäureguanidide, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament |
DE19606355A1 (de) * | 1996-02-12 | 1997-08-14 | Schering Ag | Kontrazeptive Freisetzungssysteme mit antiviraler und/oder antibakterieller Wirkung |
DE19621483A1 (de) * | 1996-05-29 | 1997-12-04 | Hoechst Ag | Substituierte 2-Naphthoylguanidine, Verfahren zur ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament |
AUPO545297A0 (en) * | 1997-03-04 | 1997-03-27 | Fujisawa Pharmaceutical Co., Ltd. | Guanidine derivatives |
US20030113352A1 (en) * | 2001-12-14 | 2003-06-19 | The Regents Of The University Of California | Neutralization of stratum corneum to treat hyperkeratotic skin lesions |
WO2004056181A1 (en) * | 2002-12-23 | 2004-07-08 | Global Cardiac Solutions Pty Ltd | Organ preconditioning, arrest, protection, preservation and recovery (2) |
WO2004087138A1 (en) * | 2003-03-31 | 2004-10-14 | Sucampo Ag | Method for treating vascular hyperpermeable disease |
WO2004112687A2 (en) | 2003-06-26 | 2004-12-29 | Biotron Limited | Antiviral acylguanidine compounds and methods |
US20070099968A1 (en) | 2004-06-26 | 2007-05-03 | Biotron Limited | Antiviral compounds and methods |
DK1902017T3 (da) * | 2005-06-24 | 2014-06-30 | Biotron Ltd | Antivirale acylguanidinforbindelser |
WO2007045572A1 (en) * | 2005-10-19 | 2007-04-26 | F. Hoffmann-La Roche Ag | N-phenyl phenylacetamide non-nucleoside reverse transcriptase inihibitors |
JP5727842B2 (ja) | 2011-04-12 | 2015-06-03 | 日野自動車株式会社 | 車両のインストルメントパネル構造 |
KR101331921B1 (ko) * | 2013-01-16 | 2013-11-21 | 에스케이플래닛 주식회사 | 영유아의 안전을 위한 스마트 인터랙션 서비스를 제공하는 장치 및 방법, 이를 이용한 시스템 |
-
2006
- 2006-06-23 DK DK06741271.8T patent/DK1902017T3/da active
- 2006-06-23 PL PL06741271T patent/PL1902017T3/pl unknown
- 2006-06-23 ES ES06741271.8T patent/ES2491217T3/es active Active
- 2006-06-23 DK DK13197255.6T patent/DK2826770T3/da active
- 2006-06-23 CN CN201310097430.5A patent/CN103274970B/zh active Active
- 2006-06-23 US US11/922,281 patent/US8669280B2/en active Active
- 2006-06-23 EP EP06741271.8A patent/EP1902017B1/en active Active
- 2006-06-23 WO PCT/AU2006/000880 patent/WO2006135978A1/en active Application Filing
- 2006-06-23 BR BRPI0612309A patent/BRPI0612309B8/pt active IP Right Grant
- 2006-06-23 CN CN2006800226410A patent/CN101208297B/zh active Active
- 2006-06-23 BR BR122020006906A patent/BR122020006906B8/pt active IP Right Grant
- 2006-06-23 JP JP2008517277A patent/JP5373392B2/ja active Active
- 2006-06-23 SG SG201004454-3A patent/SG163517A1/en unknown
- 2006-06-23 AU AU2006261593A patent/AU2006261593B2/en active Active
- 2006-06-23 NZ NZ596107A patent/NZ596107A/xx unknown
- 2006-06-23 NZ NZ564398A patent/NZ564398A/en unknown
- 2006-06-23 PL PL13197255T patent/PL2826770T3/pl unknown
- 2006-06-23 ES ES13197255T patent/ES2710662T3/es active Active
- 2006-06-23 KR KR1020147010199A patent/KR20140072101A/ko active Search and Examination
- 2006-06-23 KR KR1020087001886A patent/KR101419327B1/ko active IP Right Grant
- 2006-06-23 PT PT13197255T patent/PT2826770T/pt unknown
- 2006-06-23 CA CA2612403A patent/CA2612403C/en active Active
- 2006-06-23 PT PT67412718T patent/PT1902017E/pt unknown
- 2006-06-23 NZ NZ610715A patent/NZ610715A/en unknown
- 2006-06-23 EP EP13197255.6A patent/EP2826770B1/en active Active
- 2006-06-23 ZA ZA200800256A patent/ZA200800256B/xx unknown
-
2008
- 2008-04-17 HK HK08104365.1A patent/HK1109615A1/xx unknown
-
2012
- 2012-09-24 JP JP2012209126A patent/JP5616410B2/ja active Active
-
2013
- 2013-11-05 US US14/071,870 patent/US9440926B2/en active Active
-
2015
- 2015-07-20 HK HK15106877.8A patent/HK1206330A1/xx unknown
-
2016
- 2016-09-12 US US15/262,075 patent/US10683263B2/en active Active
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DK2826770T3 (da) | Acylguanidin-forbindelser med antiviral aktivitet | |
DK2194976T3 (da) | Hepatitis C-antivirussammensætninger omfattende 5-(1-metylpyrazol-4-yl)2-naphthoylguanidin og 2'-C-metyladenosin eller 2'-C-metylcytidin | |
JP3563106B2 (ja) | 置換ベンゾイルグアニジン、その製造法およびそれを含有する製剤 | |
PL207057B1 (pl) | Orto-podstawione związki bisarylowe, zawierające azot, preparat farmaceutyczny zawierający związki biasarylowe oraz zastosowanie związków biasarylowych | |
RU2160727C2 (ru) | Бензоилгуанидины, способ их получения, промежуточное соединение для их получения, способ ингибирования и лекарственное средство | |
AU2013205388B2 (en) | Antiviral compounds and methods | |
US20100069443A1 (en) | Compound with benzamide skeleton having cyclooxygenase-1 (cox-1)-selective inhibitory activity | |
Ren et al. | Synthesis of novel ligustrazine derivatives as NA+/H+ exchange inhibitors | |
RU2212400C2 (ru) | Орто-замещенные бензоилгуанидины и содержащие их лекарственные средства | |
WO2009129224A1 (en) | Inhibitors of protein phosphatase-1 and uses thereof | |
AU2013219202A1 (en) | Hepatitis C antiviral compositions and methods | |
JPH09328462A (ja) | オルト−置換されたベンゾイルグアニジン、それらの製造方法、医薬または診断薬としてのそれらの使用およびそれらを含有する医薬 |